NCT05356741View on ClinicalTrials.gov

To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

645

Participants

Timeline

Start Date

April 13, 2022

Primary Completion Date

August 16, 2027

Study Completion Date

August 16, 2027

Conditions
Locally Advanced or Metastatic HER2-Expressing Cancers
Interventions
DRUG

VIR-5818

Administered as IV infusion

DRUG

pembrolizumab

Administered as IV infusion

Trial Locations (10)

2031

RECRUITING

Investigational site number #101, Randwick

3000

RECRUITING

Investigational site number #100, Melbourne

28027

RECRUITING

Investigational site number #254, Madrid

28050

RECRUITING

Investigational site number #252, Madrid

28223

RECRUITING

Investigational site number #253, Pozuelo de Alarcón

31008

RECRUITING

Investigational site number #250, Pamplona

31059

RECRUITING

Investigational site number #150, Toulouse

4200-072

RECRUITING

Investigational site number #200, Porto

08023

RECRUITING

Investigational site number #255, Barcelona

08035

RECRUITING

Investigational site number #251, Barcelona

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Vir Biotechnology, Inc.

INDUSTRY